Research Summary

Prophylaxis With rFIXFc Maintains Low Bleeding Rates in Hemophilia B Patients

Edited by:

Key Highlights

  • B-MORE enrolled 151 patients across 29 centers in Europe and the Middle East.
  • Among 137 patients in the prospective analysis, the median annualized bleeding rate was 0.5, and the mean annualized bleeding rate was 0.9.
  • Median injection frequency was 52.5 per year, with median factor consumption of 2443 IU/kg/year.

Eftrenonacog alfa prophylaxis maintained low bleeding rates in people with hemophilia B in the final analysis of B-MORE, a prospective, noninterventional study published in Therapeutic Advances in Hematology. Compared with patients’ previous standard half-life factor IX prophylaxis, it showed reduced or persistently low bleeding rates, along with lower injection frequency and factor consumption.

Eftrenonacog alfa is an extended half-life recombinant factor IX Fc fusion protein (FIXFc). Investigators designed B-MORE to describe its use and effectiveness in routine practice and provide additional evidence to inform treatment strategies for people with hemophilia B.

The 24-month study enrolled patients at 29 centers across Europe and the Middle East. Eligible participants had started rFIXFc before or at enrollment, independently of study participation. Of 151 enrolled patients, more than 80% completed the study.

Descriptive analyses included patients who received at least 6 months of rFIXFc prophylaxis during the prospective period or since treatment initiation. Researchers also conducted intrapatient comparisons with previous standard half-life factor IX prophylaxis. Outcomes included annualized bleeding rate (ABR), injection frequency, factor consumption, and treatment satisfaction.

Study Findings

Among 137 patients analyzed during the prospective period, median ABR was 0.5 (interquartile range [IQR], 0.0–1.2), and mean ABR was 0.9. Median injection frequency was 52.5 injections per year (IQR, 52.2–52.6), while median factor consumption was 2443 IU/kg/year (IQR, 2022–2970). Findings were similar in the analysis covering the period since rFIXFc initiation, which also included 137 patients.

Intrapatient comparisons with prior standard half-life prophylaxis included 92 patients. Bleeding rates decreased or remained low, while injection frequency and factor consumption declined after rFIXFc initiation. Among respondents assessing satisfaction, 69 of 78 physicians (88.5%) and 90 of 100 patients (90%) were satisfied or highly satisfied with prophylaxis.

Clinical Implications

According to the authors, the final findings support rFIXFc as an effective, well-tolerated option for long-term hemophilia B prophylaxis. They characterized B-MORE as the largest real-world investigation of rFIXFc usage, with combined retrospective and prospective follow-up extending to nearly seven years.

Expert Commentary

“Final data confirm rFIXFc as an effective and well-tolerated long-term prophylactic treatment for hemophilia B,” the researchers concluded.


Reference

Glosli H, Al Saleh M, Nolan B, et al. Real-world effectiveness and usage of rFIXFc prophylaxis in hemophilia B: Final results from the B-MORE study. Ther Adv Hemat. 2026;17. doi:10.1177/20406207261493028